bi 764532
mAbexperimentalMulti-specific
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 15, 2020 (NCT04429087)
Timeline
Indications
Mechanism of action
- Delta-like protein 3INHIBITOR
DLL3 inhibitor
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05963867 | Phase 1 | Jan 31, 2024 | Boehringer Ingelheim |
| NCT06077500 | Phase 1 | Jan 25, 2024 | Boehringer Ingelheim |
| NCT05990738 | Phase 1 | Jan 11, 2024 | Boehringer Ingelheim |
| NCT06132113 | Phase 1 | Dec 20, 2023 | Boehringer Ingelheim |
| NCT05916313 | Phase 1 | Dec 13, 2023 | Boehringer Ingelheim |
| NCT05882058 | Phase 2 | Sep 25, 2023 | Boehringer Ingelheim |
| NCT05879978 | Phase 1/Phase 2 (Phase 2) | May 31, 2023 | Boehringer Ingelheim |
| NCT04429087 | Phase 1 | Jun 15, 2020 | Boehringer Ingelheim |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 8 | 8 | 2 | 2020 |
1 organizations
Page 1 / 1